Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors.
作者： Marianne E. Pavel , Ulrich Baum , Eckhart G. Hahn , Johannes Hensen
关键词:
摘要: Background: Well-differentiated neuroendocrine tumors are treated primarily with somatostatin analogs and interferon-α. It is not clear what therapy should be applied after failed biotherapy. Our aim was to establish whether patients whose rapidly progress under biotherapy may benefit from chemotherapy.
springer.com
sci-hub.se 参考文章(26)
Kjell Öberg, Advances in chemotherapy and biotherapy of endocrine tumors Current Opinion in Oncology. ,vol. 10, pp. 58- 66 ,(1998) , 10.1097/00001622-199801000-00010
P F Engstrom, P T Lavin, C G Moertel, E Folsch, H O Douglass, Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology. ,vol. 2, pp. 1255- 1259 ,(1984) , 10.1200/JCO.1984.2.11.1255
C G Moertel, Karnofsky memorial lecture. An odyssey in the land of small tumors. Journal of Clinical Oncology. ,vol. 5, pp. 1502- 1522 ,(1987) , 10.1200/JCO.1987.5.10.1502
Marie-Louise H. Fj�llskog, Dan. P. K. Granberg, Staffan L. V. Welin, Christopher Eriksson, Kjell E. �berg, Eva T. Janson, Barbro K. Eriksson, Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. ,vol. 92, pp. 1101- 1107 ,(2001) , 10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V
Anjali D Amarapurkar, Albert Davies, John K Ramage, Arie J Stangou, Derek GD Wight, Bernard C Portmann, Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis European Journal of Gastroenterology & Hepatology. ,vol. 15, pp. 139- 143 ,(2003) , 10.1097/00042737-200302000-00006
C. Liebow, C. Reilly, M. Serrano, A. V. Schally, Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase Proceedings of the National Academy of Sciences of the United States of America. ,vol. 86, pp. 2003- 2007 ,(1989) , 10.1073/PNAS.86.6.2003
Kjell Öberg, Barbro Eriksson, Eva Tiensuu Janson, Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion. ,vol. 55, pp. 64- 69 ,(1994) , 10.1159/000201204
Wey L. Leong, Janice L. Pasieka, Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. Journal of Surgical Oncology. ,vol. 79, pp. 180- 187 ,(2002) , 10.1002/JSO.10062
E Mitry, E Baudin, M Ducreux, J-C Sabourin, P Rufié, T Aparicio, P Lasser, D Elias, P Duvillard, M Schlumberger, P Rougier, Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin British Journal of Cancer. ,vol. 81, pp. 1351- 1355 ,(1999) , 10.1038/SJ.BJC.6690325
Larry K. Kvols, Metastatic carcinoid tumors and the carcinoid syndrome: A selective review of chemotherapy and hormonal therapy The American Journal of Medicine. ,vol. 81, pp. 49- 55 ,(1986) , 10.1016/0002-9343(86)90584-X